The content on this site is intended for healthcare professionals only
Prof Chanan-Khan presents, at a press conference at ASCO 2015, a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.
Read the news article and watch the interview for more.
SIOG 2024: Updates in haematology
Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients
Understanding the remaining unmet needs in a post ASCT NDMM setting
Approaches to risk stratification in high risk myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
